|
Synonyms: apitegromab-mstn | Isembyld® | SRK-015 | SRK015
apitegromab is an approved drug
Compound class:
Antibody
Comment: Apitegromab (SRK-015) is an anti-myostatin (GDF8) monoclonal antibody that is being developed by Scholar Rock [4]. Antagonism of myostatin's inhibitory effect on skeletal muscle mass is being predicted to combat muscle atrophy that is observed in patients with the neuromuscular degenerative disease spinal muscular atrophy (SMA). SRK-015 binds to promyostatin and latent myostatin in both serum and muscle [3]. In a mouse SMA model, a precursor of SRK-015 (muSRK-015P) increased muscle mass and function, which is indicative of therapeutic potential.
The primary defect in SMA occurs in defective production of survival motor neuron (SMN) protein and there are already approved drugs that are designed to promote production of functional SMN. Each drug uses a different mechanism to achieve this effect: Roche's Evrysdi® (risdiplam) is a SNM-2 splicing modifier, Biogen's Spinraza® (nusinersen) is an antisense oligonucleotide and Novartis have their gene therapy Zolgensma® (onasemnogene abeparvovec). Myostatin inhibition is likely to be considered as an adjunct to these existing therapies. Peptide sequences submitted for the INN match patented sequences that are claimed in Scholar Rock's patent WO2017120523A4, and correspond to a humanized IgG4 monoclonal referred to as Ab2 in the patent [3]. |
| References |
|
1. Crawford TO, Darras BT, Day JW, Dunaway Young S, Duong T, Nelson LL, Barrett D, Song G, Bilic S, Cote S et al.. (2024)
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study. Neurology, 102 (5): e209151. [PMID:38330285] |
|
2. Crawford TO, Day JW, De Vivo DC, Krueger JM, Mercuri E, Nascimento A, Pasternak A, Mazzone ES, Duong T, Song G et al.. (2024)
Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study. Front Neurol, 15: 1419791. [PMID:39105058] |
|
3. Donovan A, Straub M, Wawersik S. (2019)
Anti-pro/latent myostatin antibodies and methods of use thereof. Patent number: WO2017120523A4. Assignee: Scholar Rock, Inc.. Priority date: 08/01/2016. Publication date: 19/10/2019. |
|
4. Long KK, O'Shea KM, Khairallah RJ, Howell K, Paushkin S, Chen KS, Cote SM, Webster MT, Stains JP, Treece E et al.. (2019)
Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum Mol Genet, 28 (7): 1076-1089. [PMID:30481286] |
|
5. Pratley RE, Denham DS, Trivedi R, Watkins E, Connery L, Barnes J, Yu D, Hong J, Simard C, Umans K et al.. (2026)
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med, [Epub ahead of print]. [PMID:42260100] |